Different Distribution of HIV-1 Subtype and Drug Resistance Were Found among Treatment Naïve Individuals in Henan, Guangxi, and Yunnan Province of China

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Li, Lin ^a   Sun, Guoqing ^b   Liang, Shujia ^c   Li, Jianjian ^d   Li, Tianyi ^a   Wang, Zhe ^b   Liu, Wei ^c   Yang, Shaomin ^d   Liu, Yongjian ^a   Wang, Xiaolin ^a   Li, Jingyun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d AIDS Care Center (YNACC)   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD BORNE TRANSMISSION; CHINA; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; STRUCTURAL GENE; VERTICAL TRANSMISSION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84884875149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075777     Document Type: Article

References (36)

1. Broder S, (2010) The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 85: 1-18. doi:10.1016/j.antiviral.2009.10.002. PubMed: 20018391.
2. Tsibris AM, Hirsch MS, (2010) Antiretroviral therapy in the clinic. J Virol 84: 5458-5464. doi:10.1128/JVI.02524-09. PubMed: 20181709.
3. Volberding PA, Deeks SG, (2010) Antiretroviral therapy and management of HIV infection. Lancet 376: 49-62. doi:10.1016/S0140-6736(10)60676-9. PubMed: 20609987.
4. Paredes R, Clotet B, (2010) Clinical management of HIV-1 resistance. Antiviral Res 85: 245-265. doi:10.1016/j.antiviral.2009.09.015. PubMed: 19808056.
5. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y, (2005) Current progress of China's free ART program. Cell Res 15: 877-882. doi:10.1038/sj.cr.7290362. PubMed: 16354563.
6. Li HP, Guo W, Li H, Wang Z, Liu YJ, et al. (2011) [Occurrence of human immunodeficiency virus-1 resistance through a six-year surveillance in rural areas of Henan]. Zhonghua Yi Xue Za Zhi 91: 1443-1447. PubMed: 21914277.
7. Li L, Chen L, Yang S, Li T, Li J, et al. (2012) Recombination form and epidemiology of HIV-1 unique recombinant strains identified in Yunnan, China. PLOS ONE 7: e46777. doi:10.1371/journal.pone.0046777. PubMed: 23056447.
8. Yong W, Zhenzhu T, Qiu-ying Z, Wei L, Jin-hui Z, et al. (2013) Epidemiological characteristics of HIV/AIDS in Guangxi,2009-2011. South China J Prev Med 39: 6-11.
9. Yuan Y, Xing H, Wang XY, Liu CH, Yang LT, et al. (2011) [The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province]. Zhonghua Yu Fang Yi Xue Za Zhi 45: 619-624. PubMed: 22041566.
10. Su Q, Liang H, Cen P, Bi Z, Zhou P, (2012) HIV type 1 subtypes based on the pol gene and drug resistance mutations among antiretroviral-naive patients from Guangxi, Southern China. AIDS Res Hum Retrovir 28: 725-728. doi:10.1089/aid.2011.0246. PubMed: 21916807.
11. Ma L, Huang J, Xing H, Yuan L, Yu X, et al. (2010) Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces. AIDS Res Hum Retrovir 26: 1007-1013. doi:10.1089/aid.2009.0252. PubMed: 20718629.
12. Wang X, He C, Xing H, Liao L, Xu X, et al. (2012) Short communication: emerging transmitted HIV type 1 drug resistance mutations among patients prior to start of first-line antiretroviral therapy in middle and low prevalence sites in China. AIDS Res Hum Retrovir 28: 1637-1639. doi:10.1089/aid.2012.0164. PubMed: 22822770.
13. Zhao B, Han X, Dai D, Liu J, Ding H, et al. (2011) New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China. AIDS Res Hum Retrovir 27: 1047-1053. doi:10.1089/aid.2010.0119. PubMed: 21417755.
14. Li L, Lu X, Li H, Chen L, Wang Z, et al. (2011) High genetic diversity of HIV-1 was found in men who have sex with men in Shijiazhuang, China. Infect Genet Evol 11: 1487-1492. doi:10.1016/j.meegid.2011.05.017. PubMed: 21645646.
15. Li L, Liang S, Chen L, Liu W, Li H, et al. (2010) Genetic characterization of 13 subtype CRF01_AE near full-length genomes in Guangxi, China. AIDS Res Hum Retrovir 26: 699-704. doi:10.1089/aid.2010.0026. PubMed: 20528151.
16. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLOS ONE 4: e4724. doi:10.1371/journal.pone.0004724. PubMed: 19266092.
17. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21: 215-223. doi:10.1097/QAD.0b013e328011e691. PubMed: 17197813.
18. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739. doi:10.1093/molbev/msr121. PubMed: 21546353.
19. Zhang L, Chen Z, Cao Y, Yu J, Li G, et al. (2004) Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78: 13591-13599. doi:10.1128/JVI.78.24.13591-13599.2004. PubMed: 15564470.
20. Chen M, Ma Y, Duan S, Xing H, Yao S, et al. (2012) Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. BMC Infect Dis 12: 382. doi:10.1186/1471-2334-12-382. PubMed: 23270497.
21. He X, Xing H, Ruan Y, Hong K, Cheng C, et al. (2012) A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLOS ONE 7: e47289. doi:10.1371/journal.pone.0047289. PubMed: 23056619.
22. Shao Y, (2004) Report on the 2nd National HIV molecular Epidemiology Survey. Basic science update by the Chinese Ministry of Science and Technology in Chinese]. Available: http://shgy.jhgl.org. Accessed November 2007.
23. State Council AIDS Working Committee Office, UN Theme Group on AIDS in China (2008) A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2007). In: CSCAWCO B, eds.; December: 1 (2007) ed: http://www.chinaids.org.cn/n443289/n443292/6438.html.
24. Shang H, Xu J, Han X, Spero Li J, Arledge KC, et al. (2012) HIV prevention: Bring safe sex to China. Nature 485: 576-577. doi:10.1038/485576a. PubMed: 22660303.
25. Zhang Y, Lu L, Ba L, Liu L, Yang L, et al. (2006) Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLOS Med 3: e443. doi:10.1371/journal.pmed.0030443. PubMed: 17105339.
26. Wang W, Xu J, Jiang S, Yang K, Meng Z, et al. (2011) The dynamic face of HIV-1 subtypes among men who have sex with men in Beijing, China. Curr HIV Res 9: 136-139. doi:10.2174/157016211795569096. PubMed: 21361866.
27. Yao X, Wang H, Yan P, Lu Y, Lin H, et al. (2012) Rising epidemic of HIV-1 infections among general populations in Fujian, China. J Acquir Immune Defic Syndr, 60: 328-35. PubMed: 22343181.
28. Li Z, He X, Wang Z, Xing H, Li F, et al. (2012) Tracing the origin and history of HIV-1 subtype B' epidemic by near full-length genome analyses. AIDS 26: 877-884. doi:10.1097/QAD.0b013e328351430d. PubMed: 22269972.
29. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53 (Suppl 1):: S10-S14. doi:10.1097/QAI.0b013e3181c7d363. PubMed: 20104099.
30. Pingen M, Nouwen JL, Dinant S, Albert J, Mild M, et al. (2012) Therapy failure resulting from superinfection by a drug-resistant HIV variant. Antivir Ther 17: 1621-1625. doi:10.3851/IMP2267. PubMed: 22846173.
31. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, et al. (2005) HIV drug resistance acquired through superinfection. AIDS 19: 1251-1256. doi:10.1097/01.aids.0000180095.12276.ac. PubMed: 16052079.
32. Wainberg MA, Brenner BG, (2010) Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses 2: 2493-2508. doi:10.3390/v2112493. PubMed: 21994627.
33. Wainberg MA, Brenner BG, (2012) The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs. Mol. Biol Int: pp. 2012: 256982.
34. Li J, Li L, Li HP, Zhuang DM, Liu SY, et al. (2009) Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations. Chin Med J (Engl) 122: 1081-1086.
35. Turner D, Wainberg MA, (2006) HIV transmission and primary drug resistance. AIDS Res 8: 17-23. PubMed: 16736948.
36. AMJ Wensing Vercauteren J, Vijver, Dvd, Albert J, Poggensee G,et al. (Antivir Ther. 2006) Transmission of drug-resistance in Europe is characterized by single mutations and revertants. 15th International HIV Drug Resistance Workshop. Sitges, Spain: International Medical Press. pp. S111.